K-pop

KBS Radio 2 Launches New Program "Lee Seul-gi's Happy Time"

Sequel to "Sweet Drive, This Is In Ho-jin" Broadcast daily at 6:00 p.m. starting on the 17th

KIM HYUNSIK
2026-08-06 09:02:31
[Edaily Starin Reporter KIM HYUNSIK ] KBS Radio 2 announced on the 6th that its new program, “Lee Seul-gi’s Happy Time,” will premiere on the 17th.
Announcer Lee Seul-gi (Photo: KBS)
“Lee Seul-gi’s Happy Time” is the follow-up program to “Sweet Drive, This Is In Ho-jin,” hosted by In Ho-jin of the vocal group Sweet Sorrow. KBS announcer Lee Seul-gi will serve as the DJ.
KBS Radio 2 stated, “As a 16-year veteran of the broadcasting industry and a mother of two, Lee plans to share her daily life with listeners on their way home from work through relaxing music and stories closely tied to everyday life.”
Lee said, “I’m delighted to be able to interact with listeners through a live broadcast,” adding, “I’ll ensure listeners have a relaxing evening with my cheerful energy and down-to-earth charm.”
“Lee Seul-gi’s Happy Time” can be heard daily from 6:00 p.m. to 8:00 p.m. on KBS Radio 2 (106.1 MHz in the Seoul metropolitan area) and via the “Kong” app, starting with its premiere broadcast.

Economy

Corporation

IT·Science

Economy

"Aftermath of the Jensen Huang Scandal… U.S. to Impose Strict Export Controls on China"

“The key point in the Jensen Huang scandal will ultimately be that data centers were built in China and elsewhere, and cloud services were provided to Chinese companies. Given the circumstances, this …
2026-11-13 17:31:12

Corporation

Shinwon Reports Improved Third-Quarter Earnings on the Back of Strong Exports

Fashion company Shinwon(009270)continues to show improved performance, driven by strong exports. This is attributed to the company’s expansion of its production and sales infrastructure, particularly …
2026-11-13 19:00:02

IT·Science

HANDOK Inc.: Partner Company’s Rare Hypoglycemia Treatment Set to Draw Attention This Year… Results of External Collaboration Put to the Test

Resolute announced to the U.S. Securities and Exchange Commission (SEC) on the 14th (local time) that it had completed patient enrollment for the Phase 3 clinical trial of “Ersodetug.” (Source: U.S. S…
2026-11-13 15:42:02